Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$304.33|
|52 Week High||US$214.93|
|52 Week Low||US$309.99|
|1 Month Change||5.67%|
|3 Month Change||10.05%|
|1 Year Change||22.03%|
|3 Year Change||262.17%|
|5 Year Change||722.29%|
|Change since IPO||1,806.83%|
Recent News & Updates
Insulet (NASDAQ:PODD) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
|PODD||US Medical Equipment||US Market|
Return vs Industry: PODD matched the US Medical Equipment industry which returned 22.6% over the past year.
Return vs Market: PODD underperformed the US Market which returned 31.1% over the past year.
Stable Share Price: PODD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PODD's weekly volatility (4%) has been stable over the past year.
About the Company
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East.
Insulet Fundamentals Summary
|PODD fundamental statistics|
Is PODD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PODD income statement (TTM)|
|Cost of Revenue||US$332.50m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 04, 2021
|Earnings per share (EPS)||-0.44|
|Net Profit Margin||-3.06%|
How did PODD perform over the long term?See historical performance and comparison
Is Insulet undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: PODD ($304.33) is trading above our estimate of fair value ($118.43)
Significantly Below Fair Value: PODD is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PODD is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: PODD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PODD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PODD is overvalued based on its PB Ratio (45.7x) compared to the US Medical Equipment industry average (4.6x).
How is Insulet forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PODD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: PODD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PODD's is expected to become profitable in the next 3 years.
Revenue vs Market: PODD's revenue (18.8% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: PODD's revenue (18.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PODD's Return on Equity is forecast to be low in 3 years time (19.4%).
How has Insulet performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PODD is currently unprofitable.
Growing Profit Margin: PODD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PODD is unprofitable, but has reduced losses over the past 5 years at a rate of 51.3% per year.
Accelerating Growth: Unable to compare PODD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PODD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (36.1%).
Return on Equity
High ROE: PODD has a negative Return on Equity (-6.64%), as it is currently unprofitable.
How is Insulet's financial position?
Financial Position Analysis
Short Term Liabilities: PODD's short term assets ($1.3B) exceed its short term liabilities ($213.3M).
Long Term Liabilities: PODD's short term assets ($1.3B) exceed its long term liabilities ($1.3B).
Debt to Equity History and Analysis
Debt Level: PODD's debt to equity ratio (273.6%) is considered high.
Reducing Debt: PODD's debt to equity ratio has reduced from 624.3% to 273.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if PODD has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PODD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Insulet current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PODD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PODD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PODD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PODD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PODD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Shacey Petrovic (47 yo)
Ms. Shacey Petrovic has been an Independent Director at Exact Sciences Corporation since July 22, 2020. Ms. Petrovic serves as Director of Alydia Health, Inc. She is the President of Insulet Corporation si...
CEO Compensation Analysis
Compensation vs Market: Shacey's total compensation ($USD7.28M) is below average for companies of similar size in the US market ($USD11.15M).
Compensation vs Earnings: Shacey's compensation has increased whilst the company is unprofitable.
Experienced Management: PODD's management team is considered experienced (2.8 years average tenure).
Experienced Board: PODD's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PODD insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.9%.
Insulet Corporation's employee growth, exchange listings and data sources
- Name: Insulet Corporation
- Ticker: PODD
- Exchange: NasdaqGS
- Founded: 2000
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$20.960b
- Shares outstanding: 68.87m
- Website: https://www.insulet.com
Number of Employees
- Insulet Corporation
- 100 Nagog Park
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/22 22:58|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.